Section Review Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: HLA-derived peptides as a strategy for the prevention of allograft rejection

References to Primarv Literature

• ZINKERNAGEL RM, DOHERTY PC: Restriction of in vitro T- cell- mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature (1974) 248:701–702.
   PubMed Web of Science ®Google Scholar
• BJORKMAN PJ, SAPER MA, SAMRAOUI B, BENNETT WS, STROMINGER JL, WILEY DC: Structure of the human class I histocompatibility antigen, HLA-A2. Nature (1987) 329:506–512.
   PubMed Web of Science ®Google Scholar
• BJORKMAN PJ, SAPER MA, SAMRAOUI B, BENNETT WS, STROMINGER JL, WILEY DC: The foreign antigen binding site and T-cell recognition regions of class I histocom-patibility antigen. Nature (1987) 329:512–518.
   PubMed Web of Science ®Google Scholar
• FALK K, ROTZSCHKE O, RAMMENSEE HG: Cellular pep-tide composition governed by major histocompatibility complex class I molecules Nature (1990) 348:248–251.
   Google Scholar
• ROTZSCHKE O, FALK K: Naturally-occurring peptide antigens derived from the MIIC class-I-restricted proc-essing pathway. Immunol. Today (1991) 12:445–447.
   Google Scholar
• HUNT DF, HENDERSON RA, SHABANOWITZ J, SAK-AGUCHI K, MICHEL H, SEVILIR N, COX A, APPELLA E, ENGELHARD VH: Characterisation of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrome-try. Science (1992) 255:1261–1263.
   Google Scholar
• ENGELHARD VH: Structure of peptides associated with class I and class II molecules. Ann. Rev. Immunol. (1994) 12:181–207.
   PubMed Web of Science ®Google Scholar
• KRENSKY AM, WEISS A, CRABTREE G, DAVIS M, PARHAMP: Mechanisms of disease: T-lymphocyte - antigen inter-actions in transplant rejection. New Engl. J. Med. (1990) 322:510–517.
   PubMed Web of Science ®Google Scholar
• TOPHAM DJ, NAG B, ARIMILLI S, SRIRAM S: A syntheticpeptide from the third hypervariable region of MHC class II b chain as a vaccine for treatment of EAE. Proc. Natl. Acad. Sci. USA (1994) 91:8005–8009.
   PubMed Web of Science ®Google Scholar
• WINICELHAKE JL, NAG B: Trials and tribulations in thedevelopment of antigen specific therapies for rheuma-toid arthritis. Exp. Opin. Invest. Drugs (1995) 4:457–472.
   Google Scholar
• CLAYBERGER C, HOLMES N, WANG PL, KOLLER TD, PARHAM P, KRENSKY AM: Determinants recognised by human cytotoxic T-cells on a natural hybrid Class I HLA molecule. J. Exp. Med. (1985) 162:1709–1714.
   PubMedGoogle Scholar
• SALTER RD, CLAYBERGER C, LOMEN CE, KRENSKY AM, PARHAM P: In vitro mutagenesis at a single residue Introduces B- and T-cell epitopes into a Class I HLA molecule. j Exp. Med. (1987) 166: 283–288.
   PubMed Web of Science ®Google Scholar
• WAYS JP, PARHAM P: The antigenic structure of HLA-A2: an analysis with competitive binding assays and mono-clonal antibodies. J. Immunol. (1983) 131:856–863.
   PubMed Web of Science ®Google Scholar
• PARHAM P: Functional polymorphism in class I major histocompatibility complex genes. Soc. Gen. Physiol. Series (1994) 49:93–103.
   PubMedGoogle Scholar
• HOGAN KT, CLAYBERGER C, BERNHARD EJ, WALK SF, RIDGE JP, PARHAM P, KRENSKY AM, ENGELHARD VH: A panel of unique HLA-A2 mutant molecules define epi-topes recognised by HLA-A2-specific antibodies and cytotoxic T-lymphocytes. j Immunol. (1989) 142:2097–2104.
   PubMed Web of Science ®Google Scholar
• PARHAM P, CLAYBERGER C, ZORN SL, LUDWIG DS, SCHOOLNIK GK, KRENSKY AM: Inhibition of alloreactivecytotoxic T-lymphocytes by peptides from the alpha 2 domain of HLA-A2. Nature (1987) 325:625-628. First description of allogeneic inhibition by peptides corresponding to HLA sequences.
   Google Scholar
• CLAYBERGER C, PARHAM P, ROTHBARD J, LUDWIG DS, SCHOOLNIK GK, KRENSKY AM: HLA-A2 peptides canregulate cytolysis by human allogeneic T-lymphocytes. Nature (1987) 330:763-765. Generalisation of peptide inhibition; inhibition at level of the T-cell.
   Google Scholar
• KRENSKY AM: HLA-derived peptides as novel inrimuno-suppressives. Ped. Res. (1995) 38:275–279.
   PubMedGoogle Scholar
• SALTER RD, NORMENT AM, CHEN BP, CLAYBERGER C,KRENSKY AM, LITTMAN DR, PARHAM P: Polymorphism in the alpha 3 domain of HLA-A molecules affects binding to CD8. Nature (1989) 338:345–347.
   PubMedGoogle Scholar
• SALTER RD, BENJAMIN RJ, WESLEY PK, BUXTON S, GAR-RETT TPJ, CLAYBERGER C, KRENSKY AM, NORMENT AM, LITTMAN DR, PARHAM P: A binding site for the T-cell co-receptor, CD8, on the alpha 3 domain of HLA-A2. Nature (1990) 345:41–46.
   PubMed Web of Science ®Google Scholar
• NORMENT AM, SALTER RD, PARHAM P, ENGELHARD VH,LITTMAN DR: Cell-cell adhesion mediated by CD8 and MHC class I molecules. Nature (1988) 336:79–81.
   PubMed Web of Science ®Google Scholar
• CLAYBERGER C, LYU, S-C, DEKRUYFF R, PARHAM P, KREN- •SKY AM: Peptides corresponding to the CD8 and CD4 binding domains of HLA molecules block T-lymphocyte Immune responses in vitro. J. Immunol. (1994) 53:946-951. Peptides corresponding to co-receptor binding sites block the gen-eration of CTL, but do not inhibit established CTL.
   Google Scholar
• CLAYBERGER C, LYU S-C, POULETTY P, KRENSKY AM: Peptides corresponding to T-cell receptor - HLA contact regions inhibit class I restricted immune responses. Transpl. Proc. (1993) 25:477-478. First demonstration that peptides corresponding to al alpha helical sequences inhibit T-lymphocyte function in an allele non-specific manner.
   Google Scholar
• CLAYBERGER C, ROSEN M, PARHAM P, KRENSKY AM: Recognition of an HLA public determinant (Bw4) by human allogeneic cytotoxic T-Iymphocytes. J. Immunol. (1990) 144:4172–4176.
   PubMed Web of Science ®Google Scholar
• MORETTA L, CICCONE E, MORETTA A, HOGLUND P, OHLEN C, KARRE K: Allorecognition by NK cells: non-self or no self? Immunol. Today (1992) 13:300–306.
   Google Scholar
• LANIER LL, PHILLIPS JH: NK cell recognition of majorhistocompatibility complex class I molecules. Sem. Im-munol. (1995) 7:75–82.
   PubMedGoogle Scholar
• NISCO S, VRIENS P, HOYT G, LYU S-C, FARFAN F. POULETTY P, KRENSKY AM, CLAYBERGER C: Inductionof allograft tolerance in rats by an HIA class I derived peptide and cyclosporine A.]. Immunol. (1994) 152:3786-3792. Class I derived peptides induce immunologic tolerance in an animal model of transplantation.
   Google Scholar
• CUTURI MC, JOSIEN R, DOUILLARD P, PANNETIER C,CANTAROVICH D, SMIT II, MENORET S, POULETTY P, CLAYBERGER C, SOULLLLOU JP: Prolongation of allo-geneic heart graft survival in rats by administration of a peptide (La. 75–84) from the alpha 1 helix of the first domain of HLA-B701. Transplantation (1995) 59:661–669.
   Google Scholar
• BUELOW R, VEYRON P, CLAYBERGER C, POULETTY P, TOURAINE J-P: Prolongation of skin allograft survival in mice following administration of Allotrap. Transplanta-tion (1995) 59:455–460.
   PubMed Web of Science ®Google Scholar
• GAO L, WOO J, BUELOW R: Both L- and D- isomers ofAllotrap B2702 peptides prolong cardiac allograft sur-vival in mice. J. Heart Lung Transplant. (1996) 15:78–87.
   PubMedGoogle Scholar
• POULETTY P, FLOC'H R, BUELOW R, SOULILLOU J-P, SCHROEDER T, KRENSKY AM, CLAYBERGER C: A novel approach to the induction of graft acceptance: Allo-trapTm peptide therapy.]. Am. Soc. Nephrol. (1994) 5:987.
   Google Scholar
• GIRAL M, CUTURI M-C, N'GUYEN J-M, DANTAL J, BUELOWR, FLOC'H R, POULETTY P, SOULIILOU J-P: Reduction of natural killer cell cytotoxic activity in human kidney allograft recipients treated with an HLA-derived pep-tide. Proceedings of 2nd International Conference on New Trends in Clinical and Experimental Imrnunasuppression (1996):102.
   Google Scholar
• NOESSNER E, GOLDBERG J, NAFTZGER C, LYU S-C, CLAYBERGER C, KRENSKY AM: HLA-derived peptides which Inhibit T-cell function bind to members of the heat shock protein 70 family.], Exp. Med. (1996) 183:339-348. Immunomodulatory HLA-derived peptides bind to members of the heat shock protein 70 family.
   Google Scholar
• NADLER SG, TEPPER MA, SCHACTER B, MAZZUCCO CE:Interaction of the immunosuppressant deoxysper-guaBn with a member of the Hsp70 family of heat shock proteins. Science (1992) 258:484–486.
   PubMed Web of Science ®Google Scholar
• SAYEGH MIL KHOURY SK, HANCOCK WW, WEINER HL, CARPENTER CB: Induction of immunity and oral tolerance with polymorphic class II MHC allopeptkles in the rat. Proc. Natl. Acad. Sci. USA (1992) 89:7762-7766. Immune response to alloantigen can be downregulated by oral administration of class Il MHC peptides.
   Google Scholar
• WATSCHINGER B, GALLON L, CARPENTER CB, SAYEGH MH: Mechanisms of allorecognition: recognition by in vivo primed T-cells of specific major histocompatibility complex polymorphisnis presented as peptides by re-sponder antigen-presenting cells. Transplantation (1994) 57:572–577.
   PubMed Web of Science ®Google Scholar
• GALLON L, WATSCHINGER B, MURPHY B, AKALIN E, SAYEGH MH, CARPENTER CB: The indirect pathway of allorecognition: the occurrence of self-restricted T-cell recognition of allo-MHC peptides early in acute renal allograft rejection and its inhibition by conventional immimosuppression. Transplantation (1995) 59:612-616. Evidence for the indirect pathway of allorecognition in acute trans-plant rejection; also, immunogenicity of allo-MHC peptides varies with responder strain.
   Google Scholar
• REMUZZI G, PERICO N, CARPENTER CB, SAYEGH MH: Thethymic way to transplantation tolerance. J. Am. Soc. Nephrol. (1995) 5:1639–1646.
   PubMed Web of Science ®Google Scholar
• POSSELT A, BARKER C, TOMASZEWSKI J, MARKMANN JF,CHOTI MA, NAJI A: Induction of donor-specific unre-sponsiveness by intrathymic islet transplantation. Sci-ence (1990) 249:1293–1295.
   PubMed Web of Science ®Google Scholar
• REMUZZI, G, ROSSINI M, IMBERTI O, PERICO N: Kidneygraft survival in rats without inununosuppressants af-ter intrathymic glomeruLir transplantation. Lancet (1991) 337:750–752.
   PubMedGoogle Scholar
• PERICO, N, ROSSINI M, IMBERTI O, REMUZZI G: Thymusmediated immune tolerance to renal allograft is donor but not tissue specific. J. Am. Soc. Nephrol. (1992) 2:1063–1071.
   Web of Science ®Google Scholar
• OLUWOLE, SF, CHOWDHURY NC, JIN M, HARDY MA: Induction of transplantation tolerance in rat cardiac allografts by intrathymic inoculation of allogeneic sol-uble peptides. Transplantation (1994) 56:1523–1527.
   Web of Science ®Google Scholar
• SAYEGH MH, PERICO P, IMBERTI I, HANCOCK WW, CAR-PENTER CB, REMUZZI G: Thymic recognition of class II MHC aliopeptkles induces donor specific unrespon-siveness to renal allografts. Transplantation (1993) 56:461-465. Administration of MHC peptides alone, as opposed to intact alio-geneic cells, is sufficient to induce thymic tolerance.
   Google Scholar
• REMUZZI G, NORIS M, BENIGNI A, IMBERTI O, SAYEGH MH, PERICO N: Thromboxane A2 receptor antagonist abrogates donor-specific graft tolerance triggered by thymic recognition of histocompatibility allopeptides. J. Exp. Med. (1994) 180:1967–1972.
   PubMed Web of Science ®Google Scholar
• SAYEGH MH, PERICO N, GALLON L, IMBERTI O, HANCOCK WW, REMUZZI G, CARPENTER CB: Mechanisms of ac-quired thymic unresponsiveness to renal allografts: thymic recognition of immunodominant allo-MHC pep-tides induces peripheral T-cell anergy. Transplantation (1994) 58:125–130.
   PubMed Web of Science ®Google Scholar
• HANCOCK WW, KHOURY SJ, CARPENTER CB, SAYEGH MH: Differential effects of oral versus intrathymic ad-ministration of polymorphic MHC class II peptides on mononuclear and endothelial cell activation and cytok-ine expression during a delayed-type hypersensitivity response. Am.J. Pathol. (1994) 144:1149–1158.
   PubMed Web of Science ®Google Scholar
• KHOURY SJ, GALLON L, CHEN WANJUN, BETRES K, RUSSELL ME, HANCOCK WW, CARPENTER CB, SAYEGHMH, WEINER HL: Mechanisms of acquired thymic tolerance in experimental autoimmune encephalomyelitis: Thymic dendritic-enriched cells induce specific pe-ripheral T-cell unresponsiveness in vivo. J. Exp. Med. (1996) 182:357-366. Thymic dendritic-enriched cells mediate the induction of acquired thymic tolerance.
   Google Scholar
• WEINER HL, FRIEDMAN A, MILLER A, KHOURY SJ, AL-SAB-BAGH A, SANTOS L, SAYEGH MH, NUSSENBLATT RB, TRENTHAM DE, HAFLER DA: Oral Tolerance: Immu-nologic mechanisms and treatment of animal and hu-man organ specific autoimmune diseases by oral administration of autoantigens. Ann. Rev. kimono!. (1994) 12:809–837.
   Web of Science ®Google Scholar
• SAYEGH MH, ZHANG ZJ, HANCOCK WW, KWOK CA, CARPENTER CB, WEINER HL: Orally administered alloan-tigen down-regulates the immune response to histo-compatibility antigens and prevents sensitization by skin allografts. Transplantation (1992) 53:163–166.
   PubMed Web of Science ®Google Scholar
• HANCOCK WW, SAYEGH MH, KWOK CA, WEINER HI., CARPENTER CB: Oral but not intravenous alloantigen prevents accelerated allograft rejection by selective intragraft TH2 cell activation. Transplantation (1993) 55:1113–1118.
   Google Scholar
• SAYEGH ME, KRENSKY AM: Novel immunotherapeuticstrategies using MHC derived peptides. Kidn. Intl. (1996) 49:513–S20.
   Google Scholar
• MURPHY B, AKALIN E, WATSCHINGER B, CARPENTER CB, SAYEGH MH: Inhibition of the alloimmune response with synthetic non-polymorphic class II MHC peptides. Transplant. Proc. (1995) 27:409.
   PubMed Web of Science ®Google Scholar
• BOYTIM M, GOLDBERG J, LYU S-C, KRENSKY AM, CLAY-BERGER C: Immunomodulatory HLA class II derived peptides inhibit cytokine gene transcription. Manuscript in preparation. (1996).
   Google Scholar